Metronidazole Lacks Activity against *Mycobacterium tuberculosis* in an In Vivo Hypoxic Granuloma Model of Latency

Lee G. Klinkenberg,1 Lesley A. Sutherland,1 William R. Bishai,1,2 and Petros C. Karakousis1,2

1Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, and 2Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

During human latent tuberculosis (TB) infection, dormant bacilli putatively reside within the hypoxic environment of caseating lung granulomas. The anaerobic drug metronidazole has antituberculous activity under hypoxic conditions in vitro but lacks activity against murine TB. In the present study, we used the hypoxia marker pimonidazole to demonstrate the presence of hypoxia in a novel in vivo granuloma model of *Mycobacterium tuberculosis* latency. We also used a high-throughput, microarray-based technique to identify mycobacterial genes essential to hypoxia and showed that this in vivo model correctly identified 51% of hypoxia-attenuated mutants, a significantly larger percentage than that identified by the mouse (29%) and guinea pig (29%) aerosol models of TB. Although isoniazid showed activity during the first 28 days of therapy and rifampin was active against dormant bacilli after the establishment of hypoxia, metronidazole showed no antituberculous activity in this in vivo hypoxic granuloma model of *M. tuberculosis* dormancy.

Latent tuberculosis (TB) infection (LTBI) poses a major obstacle to TB eradication [1, 2]. Human LTBI is characterized by tuberculin test positivity without clinical or radiographic findings [3]. LTBI apparently comprises a paucibacillary population of dormant organisms with reduced replication and metabolism [4] within host granulomas [5].

Hypoxia may be a primary microenvironmental condition responsible for *Mycobacterium tuberculosis* dormancy within granulomas associated with human LTBI [6]. Unlike LTBI, most active TB infections occur in well-oxygenated body sites [6], and cavities open to airways generally harbor greater bacillary numbers [7]. Furthermore, disease reactivation usually involves the highly oxygenated upper lung lobes [6].

Exposure of *M. tuberculosis* to progressive hypoxia in vitro induces a dormant state characterized by reduced replication and metabolism analogous to that postulated for bacilli in human LTBI. In the best-characterized model, Wayne and Hayes [8] and Wayne [9] have shown that, when the dissolved oxygen content drops below 1%, *M. tuberculosis* enters microaerophilic nonreplicating persistence (NRP) stage 1 [8], which is characterized by termination of DNA synthesis and thickening of the outer cell wall. As the dissolved oxygen content drops to ~0.06%, the bacilli enter NRP stage 2 and demonstrate reduced susceptibility to standard antituberculous drugs but increased susceptibility to nitroimidazole drugs [8, 10].

Metronidazole becomes reductively activated by the pyruvate-ferredoxin oxidoreductase system under anaerobic conditions [11]. Despite activity against dormant bacilli under progressive-hypoxia conditions in vitro, metronidazole appears to be inactive against *M. tuberculosis* in vivo. Specifically, metronidazole lacks activity against bacilli within infected bone marrow–derived macrophages and does not kill bacilli in mouse lungs.
during the active or containment phases of disease [12]. Furthermore, metronidazole lacks sterilizing activity in the Cornell model of murine TB persistence [12, 13]. However, the poor antituberculous activity of metronidazole in the mouse model may be explained by the absence of hypoxia in mouse lungs during TB infection [14, 15].

We developed a novel in vivo granuloma model of *M. tuberculosis* dormancy (the mouse hollow-fiber model) in which bacilli achieve stationary-state colony-forming unit counts, decreased metabolic activity, and greater susceptibility to rifampin than isoniazid, which are key features of human LTBI [16]. In this model, host inflammatory cells are recruited around the subcutaneously implanted semidiffusible fibers, resulting in progressive formation of perifiber granulomas. Dormant organisms in this model show significant up-regulation of the DosR regulon, which is also induced on hypoxic exposure of bacilli in vitro [17].

In the present study, we characterized the oxygen content in the mouse hollow-fiber model by means of the hypoxia marker pimonidazole as well as a high-throughput microarray-based technique to evaluate the survival of several different *M. tuberculosis* mutants containing mutations in hypoxia-induced genes. Having found evidence of hypoxia using these immunohistochemical and mutant-survival approaches, we tested the tuberculocidal activity of metronidazole in the mouse hollow-fiber model.

**METHODS**

**Strain selection criteria.** Insertion mutagenesis of *M. tuberculosis* CDC1551 by means of the Himar1 transposon (Tn) yielded a library of ~1500 unique mutants [18]. Tn insertion sites were identified by sequencing [18, 19]. Available mutants were cross-referenced with a list of hypoxia-induced genes compiled from published data [20–24], and 107 mutants were selected for this study (tables 1 and 2).

**Bacterial strains and growth conditions.** Tn mutants were grown individually to mid-log phase at 37°C in Middlebrook 7H9 liquid broth supplemented with oleic acid–albumin–dextrose–catalase (Becton Dickinson), 0.05% Tween-80, and 0.1% glycerol. Equal volumes of same-density cultures were mixed, forming 2 pools (tables 1 and 2). Glycerol was added to a final concentration of 10%, and aliquots (optical density [OD] at 600 nm, 0.4) were frozen at −80°C.

**Progressive-hypoxia model of infection.** Each Tn mutant pool culture was diluted to ~1 × 10^6 cfu/mL, as determined by OD_{600}. A culture with a ratio of head-space air to medium volume of 0.5 was grown in individual test tubes containing a magnetic stir bar and sealed with rubber stoppers. The cultures were incubated upright at 37°C with stir bars spun at a speed sufficient for uniform suspension of organisms without agitating the culture surface. The reduction and decolorization of the methylene blue dye served as a visual indicator of oxygen levels corresponding to NRP stage 2 [8], and the day on which this occurred was defined as day 0. Samples were collected on day 0 (input pool) and on day 28 (output pool) after color change. Sample collection, done by piercing the rubber stoppers, did not introduce atmospheric oxygen into the tubes, as assessed by maintenance of the decolorized dye state.

**Animals.** Female SKH1 hairless immunocompetent mice (7–8 weeks old) and female outbred Hartley guinea pigs (300–350 g) were purchased from Charles River Laboratories. Animals were maintained under pathogen-free conditions and were fed water and chow ad libitum. All procedures followed protocols approved by the Institutional Animal Care and Use Committee of the Johns Hopkins University.

**Aerosol infection of animals.** Animals were aerosol infected with the pools of Tn mutants by means of a Glas-Col inhalation exposure system, calibrated to deliver ~500 cfu/lung on day 1 after infection. Animals were killed on day 14 (input pool) and on day 56 (output pool), and organs were removed aseptically. Day 14 was chosen as the input time point to allow for adequate representation of each individual Tn mutant before organized granuloma formation in animal lungs. Guinea pig organs were stored at −80°C until the time of homogenization. Guinea pig lungs were homogenized in 5–10 mL of PBS by means of a Polytron homogenizer (Kinematica) with a 12-mm generator (Brinkman) in a biosafety level 3 Glovebox cabinet (Germfree). Mouse lungs were homogenized using glass homogenizers.

**Hollow-fiber infection of mice.** Approximately 1 × 10^4 organisms of 2 separate Tn mutant pools from the same mixed culture as the aerosol infections were inoculated into each individual hollow fiber (~200 cfu per mutant). Fibers were heat sealed and implanted subcutaneously, as described elsewhere [16, 25, 26]. Mice were killed and fibers recovered on day 14 (input pool) and on day 56 (output pool) after fiber implantation.

**Mutant pool recovery and genomic preparations.** Samples were plated on supplemented Middlebrook 7H10 plates (Fisher). Log_{10}-transformed colony-forming unit counts were used to calculate averages and SDs for graphing purposes. From 500 to 10,000 colonies per sample (as available) were scraped from plates and pooled, and genomic DNA was extracted as described.

<table>
<thead>
<tr>
<th>Table 1. <em>Himar1</em> transposon mutants included in pool 1.</th>
</tr>
</thead>
<tbody>
<tr>
<td>The table is available in its entirety in the online edition of the <em>Journal of Infectious Diseases</em>.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2. <em>Himar1</em> transposon mutants included in pool 2.</th>
</tr>
</thead>
<tbody>
<tr>
<td>The table is available in its entirety in the online edition of the <em>Journal of Infectious Diseases</em>.</td>
</tr>
</tbody>
</table>

276 • JID 2008:198 (15 July) • Klinkenberg et al.
elsewhere [27]. DNA samples were processed according to the DeADMAn (designer arrays for defined mutant analysis) technique [28]. Samples generated from input and output pools for each experiment were labeled with different fluorochromes, combined, and hybridized to mutant-specific 60mer microarrays. Control probes were printed onto the array as a mix of all 107 mutant-specific 60mers and used to normalize the ratio of signal between the 2 channels. The variance of each ratio between at least 2 technical replicates of 2 biological replicates was analyzed using SAM software (version 3.01) [29]. Probes with greater signal from the input pool than from the output pool were determined to reflect attenuation of a particular Tn mutant if the corresponding q value was less than the false discovery rate, selected such that the mean number of false discoveries was <1 gene per array.

**Metronidazole chemotherapy.** Hollow fibers containing ~1000 *M. tuberculosis* CDC1551 bacilli were implanted into SKH1 mice. Antibiotic therapy was initiated 14 days after implantation. Groups of mice were treated daily (5 days per week) by esophageal cannulation (gavage) with isoniazid (25 mg/kg/day), rifampin (10 mg/kg/day), metronidazole (100 mg/kg/day), or pyrazinamide (150 mg/kg/day). A control group received deionized water daily by gavage. Mice were killed and hollow fibers retrieved on days −13, −7, 0, 7, 14, 28, and 56 relative to initiation of treatment. Hollow-fiber contents were plated on 7H10 plates, and bacterial colonies

---

**Figure 1.** Pimonidazole staining of perifiber tissues. Hollow fibers were recovered on days 7 (A), 14 (B), and 28 (C) after implantation. Also shown are positive controls comprising cross-sections of mouse kidney on days 7 (D) and 14 (E) after fiber implantation and hollow fiber containing vehicle recovered on day 28 after implantation (F). Arrows indicate hollow fiber wall. The bracket in panel C shows the layer of greatest inflammation and pimonidazole staining.

**Figure 2.** Colony-forming unit counts from hollow fibers used for pimonidazole immunohistochemical analysis. Separate groups of mice received hollow fibers containing ~10 cfu (low dose), ~1 × 10^3 cfu (mid-dose), and ~3.5 × 10^4 cfu (high dose). Values are log_{10}-transformed colony-forming unit counts with SDs. Results of pimonidazole staining for these experiments are presented in figure 3.
were enumerated after 3 weeks. Results are representative of 2 independent experiments.

**Pimonidazole immunohistochemical analysis.** Fibers containing \( \sim 3000 \) cfu of bacilli were implanted into one group of 20 SKH1 mice, and groups of 5 animals were killed on days 1, 7, 14, and 28 after implantation. Three additional groups of 15 mice received fibers containing \( \sim 10, \sim 1 \times 10^3, \) or \( \sim 1 \times 10^4 \) cfu, and 5 mice from each group were killed on days 1, 14, and 28 after implantation. Mice received pimonidazole (Chemicon International; 60 mg/kg by intraperitoneal injection) 2 h before being killed. Hollow-fiber contents from 3 mice per time point were used for colony-forming unit enumeration. The remaining hollow fibers were removed in situ and placed in 10% neutral buffered formalin. Paraffin-embedded tissue sections were visualized for pimonidazole staining according to manufacturer recommendations.

**RESULTS**

**Figure 3.** Dependence of perifiber hypoxia on the no. of intrafiber bacilli. Shown are cross-sections of hollow fibers containing a low dose (A), mid-dose (B), or high dose (C) of colony-forming units or \( \sim 3.5 \times 10^4 \) heat-killed organisms (D). The arrow in panel A indicates the location of missing hollow-fiber wall. The arrows in panels B–D indicate hollow-fiber walls. The brackets in panels A–C indicate tissue layers containing pimonidazole staining.

| Table 3. Himar1 transposon mutant survival in 4 models, including the in vitro progressive-hypoxia model (reference). |
|---|---|---|
| Pool, model | Hypoxia-attenuated mutants in each model, proportion (%) | Hypoxia-attenuated mutants in each model, proportion (%) |
| Pool 1 | Mouse hollow-fiber model | Mouse hollow-fiber model |
| Hypoxia reference model | 21/21 (100) | 14/21 (67) |
| Mouse aerosol model | 14/21 (67) | 6/21 (29) |
| GP aerosol model | 10/21 (48) | 6/21 (29) |
| Pools 1 and 2 | Hypoxia reference model | 74/74 (100) |
| Mouse hollow-fiber model | 67/74 (51) |

**Perifiber tissue staining with the hypoxia marker pimonidazole.** To test directly for the presence of microaerophilic conditions in the mouse hollow-fiber model, we used the hypoxia marker pimonidazole. This 2-nitroimidazole becomes activated by mammalian nitroreductases and stably binds to cellular proteins at tissue pO2 levels \(<10 \text{ mm Hg} \) [30]. This binding can be detected in tissue sections by immunostaining with a monoclonal antibody to pimonidazole adducts. Tissue pimonidazole adducts yield chromogenic production of a brown color through a horseradish peroxidase–linked reaction. Interestingly, the hollow-fiber walls appeared brown in all samples, even in the absence of primary antibody.

In a preliminary experiment, \( \sim 1 \times 10^3 \) bacilli were encapsulated and implanted subcutaneously in mice. Although pi-
monodiazole adducts were undetectable on day 7 or 14 after fiber implantation (figure 1A and 1B), perifiber staining was observed on day 28 in fibers containing live bacilli (figure 1C) but not in those containing vehicle (figure 1D). Negative in situ fiber staining results are accompanied by corresponding positively staining kidney sections (figure 1D and 1E) containing hypoxic renal tubular cells [31].

To determine whether hypoxia in the mouse hollow-fiber model is a dose-dependent phenomenon, hollow fibers containing ~10 cfu (low dose), ~1 × 10^2 cfu (mid-dose), or ~1 × 3.5 × 10^4 cfu (high dose) were implanted subcutaneously into separate groups of mice. Control mice received fibers containing ~3.5 × 10^4 heat-killed bacilli. As shown in figure 2, the total number of colony-forming units increased <10-fold over a 28-day period (for high dose, P = .03; for mid-dose, P = .09) except in the low-dose group, where the intrafiber colony-forming unit count reached ~1 × 10^3 by day 28 after fiber implantation (P < .002). The degree of perifiber cellular inflammation and pimonidazole staining intensity on day 28 appeared to directly correlate with the number of encapsulated live bacilli on day 1 (figure 3).

M. tuberculosis genes required for survival during hypoxia and in animal models. Genomewide expression analysis using microarrays provides a powerful means to study adaptive bacterial survival strategies in response to various stress conditions [32]. M. tuberculosis gene regulation during hypoxia has been monitored in vitro [20–24], revealing induction of genes potentially involved in bacillary survival under these conditions. We hypothesized that M. tuberculosis genes induced during hypoxia may be important for mycobacterial hypoxic survival.

We screened an archived library of ~1500 unique M. tuberculosis CDC1551 Tn insertion mutants [18] for mutations in hypoxia-induced genes [20–24] and selected a total of 107 different mutants, which were split into 2 pools (tables 1 and 2). These mutants were tested for survival in a reference model of progressive hypoxia in vitro [8], using a high-throughput microarray-based approach termed DeADMan [28]. These mutants also were tested for survival in the mouse hollow-fiber model, and a subset of mutants were tested in the mouse and guinea pig aerosol models of infection. Mutant survival patterns in each model were compared with those in the reference model.

Of the 107 mutants tested in the reference model, 74 were significantly attenuated (mean false-positive results per array <1) relative to the wild-type strain by day 28 after entry of the organisms into NRP stage 2 (table 3). Fifteen of the 74 mutant strains were grown individually in this model to confirm the microarray survival data from the pooled groups. Thirteen of these 15 Tn mutants showed reduced colony-forming unit counts relative to that of the isogenic wild-type strain by day 28 after entry into NRP stage 2 (table 3). The reduction in colony counts correlated with the number of encapsulated live bacilli on day 1 (figure 3).

Table 4. Survival of individual Himar1 transposon mutants in the hypoxia reference model.

<table>
<thead>
<tr>
<th>MT</th>
<th>Rv</th>
<th>Name</th>
<th>Models attenuateda</th>
<th>Fold attenuationb</th>
</tr>
</thead>
<tbody>
<tr>
<td>MT0023 Rv0020c</td>
<td>TB39.8</td>
<td>R, Mo HF, Mo Aero</td>
<td>10.64</td>
<td></td>
</tr>
<tr>
<td>MT0595 Rv0569</td>
<td>. . .</td>
<td>R, Mo HF, Mo Aero</td>
<td>2.30</td>
<td></td>
</tr>
<tr>
<td>MT0607 Rv0578c</td>
<td>PE_PGRS7</td>
<td>R</td>
<td>1.87</td>
<td></td>
</tr>
<tr>
<td>MT0845 Rv0823c</td>
<td>. . .</td>
<td>R, Mo HF</td>
<td>2.07</td>
<td></td>
</tr>
<tr>
<td>MT0909 Rv0886</td>
<td>fprB</td>
<td>R, Mo HF, Mo Aero</td>
<td>3.57</td>
<td></td>
</tr>
<tr>
<td>MT1161 Rv1129c</td>
<td>. . .</td>
<td>R, Mo HF</td>
<td>2.00</td>
<td></td>
</tr>
<tr>
<td>MT1283 Rv1245c</td>
<td>. . .</td>
<td>R, Mo HF</td>
<td>2.56</td>
<td></td>
</tr>
<tr>
<td>MT1449 Rv1405c</td>
<td>. . .</td>
<td>R</td>
<td>&lt;1.00</td>
<td></td>
</tr>
<tr>
<td>MT1944 Rv1894c</td>
<td>. . .</td>
<td>R, Mo HF, GP Aero</td>
<td>36.92</td>
<td></td>
</tr>
<tr>
<td>MT2084 Rv2025c</td>
<td>. . .</td>
<td>R, GP HF, GP Aero</td>
<td>&lt;1.00</td>
<td></td>
</tr>
<tr>
<td>MT2090 Rv2031c</td>
<td>hspX/acr</td>
<td>R, Mo HF</td>
<td>8.30</td>
<td></td>
</tr>
<tr>
<td>MT2137 Rv2077c</td>
<td>. . .</td>
<td>R, Mo HF, GP Aero</td>
<td>4.25</td>
<td></td>
</tr>
<tr>
<td>MT2940 Rv2873</td>
<td>mptB3</td>
<td>R, Mo Aero, GP Aero</td>
<td>3.06</td>
<td></td>
</tr>
<tr>
<td>MT3220 Rv3134c</td>
<td>. . .</td>
<td>R, Mo HF</td>
<td>150.73</td>
<td></td>
</tr>
<tr>
<td>MT3851 Rv3743c</td>
<td>ctpJ</td>
<td>R, Mo Aero</td>
<td>1.19</td>
<td></td>
</tr>
</tbody>
</table>

NOTE. GP Aero, guinea pig aerosol model; HF, mouse hollow-fiber model; Mo Aero, mouse aerosol model; R, in vitro progressive-hypoxia model (reference).

a Models in which each particular mutant was found to be attenuated by DeADMan (designer arrays for defined mutant analysis; see Methods for details).
b Values represent fold attenuation in the reference model at 28 days relative to day 0, determined by enumeration of colony-forming units for individually grown mutant strains.
The 2 Tn mutant pools (tables 1 and 2) were next tested in the mouse hollow-fiber model. Total intrafiber colony-forming unit counts for both mutant pool 1 and 2 remained stable between days 14 and 56 after hollow-fiber implantation (for pool 1, \( P = .14 \); for pool 2, \( P = .18 \)) (figure 4A). Of the 21 attenuated mutants in the reference model, 14 (67%) were attenuated relative to the wild-type strain by day 56 in the mouse hollow-fiber model (table 3). Of the 74 total mutants found to be defective for survival in the reference model, 38 (51%) also were attenuated relative to the wild-type strain by day 56 in the mouse hollow-fiber model (table 3). An additional 29 mutants among both pools showed reduced survival compared with the wild-type strain by day 56 in the mouse hollow-fiber model but not in the reference model, presumably reflecting conditions present in the former model but absent in the latter.

Recent studies have reported hypoxia in guinea pig tuberculous lung lesions [33] but not in mouse lung lesions [14, 15]. We hypothesized that Tn mutants containing mutations in genes required for microaerophilic survival of \( M. \) tuberculosis would show an attenuated phenotype in guinea pig lungs but not in mouse lungs. Guinea pigs and mice were infected with Tn mutant pool 1 by aerosol, and lung samples were collected for colony-forming unit enumeration (figure 4B) and mutant survival analysis. Between days 14 and 56, colony-forming unit counts in mouse lungs remained relatively stable (\( P = .64 \)), consistent with bacillary growth containment after the onset of adaptive immunity [34]. Of the 21 Tn mutants found to be attenuated in the reference model, 4 (19%) were attenuated in guinea pig lungs relative to the wild-type strain by day 56 after infection. Six (29%) of the 21 hypoxia-attenuated mutants showed reduced survival in mouse lungs relative to the wild-type strain by day 56 after infection (table 3).

Only the mutant containing a Tn insertion in Rv2873, which encodes the highly immunogenic cell-surface lipoprotein mpt83 [35], was attenuated in both mouse and guinea pig lungs. A mutant with a Tn insertion in the narG gene, the product of which is involved in the alternate respiration nitrate-reduction pathway, was attenuated only in the mouse hollow-fiber model and not in the other models tested. Mutants with Tn insertions in Rv2031c, which encodes HspX (\( \alpha \)-crystallin), and in Rv3134c, the gene immediately upstream of dosR/devR, were attenuated only in the reference and mouse hollow-fiber models and not in the mouse or guinea pig aerosol models.

**Metronidazole activity in the mouse hollow-fiber model.** On exposure to progressive hypoxia in vitro, \( M. \) tuberculosis becomes phenotypically tolerant to the first-line antituberculous agents isoniazid and rifampin and increasingly susceptible to metronidazole [8, 10]. Given the positive tissue-staining results with pimonidazole in the mouse hollow-fiber model as well as the relatively high number of hypoxia-attenuated Tn mutants identified in this model compared with the mouse aerosol model, we next tested the activity of metronidazole against \( M. \) tuberculosis in the mouse hollow-fiber model. Beginning 14 days after fiber implantation, mice received therapy 5 days per week with isoniazid (25 mg/kg), rifampin (10 mg/kg), pyrazinamide (150 mg/kg), or metronidazole (100 mg/kg), and control mice received vehicle by gavage. As demonstrated in figure 5, metronidazole had no significant activity against bacilli during the first 56 days after infection. Isoniazid had the greatest bactericidal activity during the first 28 days after fiber implantation (\( P < .01 \)), with no activity thereafter (\( P = .47 \)). Conversely, rifampin showed minimal activity during the first 28 days (\( P = .7 \)) but reduced intrafiber colony-forming unit counts by 2 log\(_{10}\) by day 56 after implantation (\( P < .05 \)). Consistent with data from the standard mouse model [36], pyrazin-
amide alone had no bactericidal activity against hollow fiber-encapsulated *M. tuberculosis*.

**DISCUSSION**

Exposure of *M. tuberculosis* to progressive hypoxia induces a nonreplicating persistent state characterized by reduced susceptibility to isoniazid and rifampin, which is analogous to human LTBI. However, this in vitro model has been criticized because the organisms become susceptible to metronidazole, yet this antibiotic lacks tuberculocidal activity in the murine model [12, 13]. Data are lacking to support its activity against human LTBI. In addition, in vitro models cannot accurately simulate the complex host-pathogen interactions involved in bacillary containment during human LTBI. We have developed a novel in vivo granuloma model of LTBI (the mouse hollow-fiber model) in which bacillary growth containment is partially immune mediated and the organisms exhibit a dormancy phenotype characteristic of human LTBI [16]. Consistent with the presence of microaerophilic conditions in this model, the organisms show significant up-regulation of the DosR regulon. We used the hypoxia-specific marker pimonidazole to directly demonstrate reduced tissue oxygen content in this in vivo model. The findings of *M. tuberculosis* dose-dependent pimonidazole staining as well as the absence of cellular inflammation and pimonidazole staining surrounding fibers containing heat-killed bacilli are consistent with active secretion and extracellular diffusion of *M. tuberculosis* soluble factors leading to host inflammatory cell recruitment, perifiber granuloma formation, and ensuing hypoxia. Consistent with previous data [37], our data suggest a role for hypoxia in promoting *M. tuberculosis* dormancy beyond day 28 in this model, after which time the organisms become phenotype resistant to isoniazid but susceptible to rifampin.

To our knowledge, this is the first study in which the accuracy of stress-induced *M. tuberculosis* gene expression in predicting gene function was tested systematically on a large scale. We investigated the role played by various hypoxia-induced genes in mycobacterial survival under microaerophilic conditions thought to be present in human caseous TB lesions. Identification of *M. tuberculosis* genes essential for hypoxic survival potentially provides a basis for rational drug design targeting dormant organisms in human LTBI. Approximately 69% (74/107) of all hypoxia-induced genes were found to be essential for survival during progressive hypoxia. This percentage is significantly higher than that observed using random Tn mutant pools under various stress conditions (25%–30%; authors’ unpublished data), consistent with our original hypothesis that mycobacterial gene induction predicts gene essentiality under the same stress conditions.

Among the *M. tuberculosis* genes identified as being essential for bacillary survival during hypoxia were Rv3134c, Rv0823c, Rv1129, Rv1894c, and Rv0020c. Rv3134c is directly upstream of both genes of the 2-component response regulator, dosR/dosS, raising the possibility that its disruption might have polar effects on genes downstream of this operon, which is required for *M. bovis* survival under hypoxic conditions [38]. The genes Rv0823c and Rv1129c encode putative transcriptional regulators that...
may be involved in DosR-independent hypoxic gene regulation. The Rv0020c-encoded protein is predicted to have a forkhead-associated domain, which is a phosphopeptide-binding motif and putative nuclear signaling domain present in many regulatory proteins. The conserved hypothetical protein encoded by Rv1894c has weak similarity to some oxidoreductases. Additionally, each Tn mutant tested that contained an interruption of a member of the DosR regulon (Rv0079, Rv0081, Rv0569, Rv1736c, Rv2029c, Rv2031c, Rv2626c, and Rv3134c) was attenuated during hypoxia, further corroborating the importance of the DosR regulon in the adaptation of M. tuberculosis to hypoxia.

Consistent with greater hypoxia in the mouse hollow-fiber model, more hypoxia-attenuated mutants were detected in this model relative to the mouse and guinea pig aerosol models. Surprisingly, the guinea pig model was not superior to the standard mouse model in detecting such mutants. One explanation is potential variability in pathology and tissue microenvironments throughout guinea pig lungs, such that distinct bacillary populations experience different oxygen tensions. Another possibility is that granuloma caseation was not complete at the output sample time points selected and that more hypoxia-attenuated mutants would be detected at later time points.

The findings of metronidazole inactivity in the murine model of TB [12, 13] have been criticized by proponents of the antituberculous activity of the drug, because mouse TB lesions do not achieve the degree of hypoxia necessary for drug activation [14, 15]. Here, we report no antituberculous activity of metronidazole in a novel in vivo granuloma model of M. tuberculosis dormancy, despite immunohistochemical and mutant survival–based evidence of hypoxia. There are several potential explanations for our results. Because intrafibre metronidazole concentrations were not directly measured, it is possible that intrafibre bacilli received suboptimal drug exposure. In this study, isoniazid and rifampin showed activity against intrafibre bacilli, suggesting bioavailability of these drugs following gavage. The oral metronidazole dose we used (100 mg/kg) equals or exceeds that used in previous murine TB studies [12, 13] and is greater than that shown to have activity against Bacteroides fragilis and Neisseria gonorrhoeae [39, 40] subcutaneous abscesses in mice, suggesting bioavailability of the drug in the subcutaneous space after oral administration. Alternatively, metronidazole may have poor penetration into granulomatus lesions. In that case, however, the drug would be expected to have minimal activity against persistent bacilli in human TB infection, because these organisms are postulated to inhabit the caseous and necrotic cores of granulomas. Finally, tissue oxygen levels in the mouse hollow-fiber model may be microaerophilic but not sufficiently hypoxic to permit reductive activation of metronidazole.

It remains to be conclusively demonstrated whether persistent bacilli in human TB infection dwell in caseous and necrotic lesions and whether these lesions are sufficiently hypoxic to permit metronidazole activation. Ultimately, the utility of metronidazole as an antituberculous drug can only be addressed directly in a prospective, randomized clinical trial.

References